PerkinElmer Expands Maternal Health Technology for Early Identification of Patients at Risk for Preeclampsia.

BOSTON -- Secures Global Rights for Prospective Preeclampsia BioMarker; Provides Potential Breakthrough Technology for Women

PerkinElmer, Inc. (NYSE: PKI), a world leader in Health Sciences and Photonics, today announced that it has secured the exclusive global rights to Placental Protein 13 (PP13), a new prospective biomarker for identifying patients at risk for preeclampsia developed by Diagnostic Technologies Ltd. (DTL), a developer of diagnostic kits and devices for monitoring pregnancies at risk.

PerkinElmer's ultimate goal is to provide an early marker for preeclampsia that will accelerate the identification of potential treatments at the onset of the disease process and allow healthcare professionals to better manage high-risk pregnancies. Further testing of PP13 will determine whether it can detect the predisposition for preeclampsia to allow for such improved patient management.

Preeclampsia affects five to seven percent of all pregnant women and represents a serious challenge for obstetricians and prenatal and diagnostic laboratories. The threatening disorder can result in: loss of life; blindness; motor and mental disorders or premature newborns; pregnancy hypertension; and kidney, liver & cardiovascular malfunctioning. It is estimated that nearly U.S.$30 billion is spent today in healthcare costs to treat women with preeclampsia and their newborns.

"PerkinElmer is the market leader in prenatal risk assessment, and is committed to providing comprehensive maternal health solutions to protect at-risk women," said Robert F. Friel, President of PerkinElmer Life and Analytical Sciences. "This new partnership with Diagnostic Technologies holds the promise to provide early identification of patients at risk for preeclampsia and facilitate the adoption of protective measures before complications develop."

Unlike other potential markers, detectable only a few weeks before clinical symptoms appear, the new PP13 marker appears to be manifested earlier in the pregnancy. Preliminary research data shows that measuring PP13 in a blood sample during the routine prenatal testing in the first trimester might lead to as high as a 90 percent identification rate in women who are at risk. In addition, PP13 appears to identify patients at risk for both forms of the disorder, including restricted fetal growth preeclampsia and normal fetal growth preeclampsia.

"According to CDC National Birth Statistics, preeclampsia is the second most frequent cause of maternal death during pregnancy," said Dr. Hamutal Meiri, CEO of Diagnostic Technologies Ltd. "Our partnership with PerkinElmer will contribute to the effort to establish an important new marker for this disorder that could help raise the standard of care of maternal health during pregnancy."

"At present, there is no proven effective method for the prevention of preeclampsia, but there is some evidence that the prophylactic use of low-dose aspirin, starting from the first-trimester of pregnancy, could reduce the prevalence of the disease," said Professor Kypros Nicolaides, Director of the Fetal Medicine Foundation. "The preliminary data on PP13 is encouraging. It is now necessary to validate that data and undertake a large screening study by maternal serum PP13 and uterine artery Doppler, and randomize women in the high-risk group to determine if early intervention can truly reduce the prevalence of the disease."

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our ability to identify a purchaser of the Company's semiconductor business, negotiate and consummate the sale of such business, including obtaining regulatory approvals; (2) economic and geopolitical forces that may limit any continued or expected economic or end market strengthening or recoveries; (3) risks related to our failure to introduce new products in a timely manner; (4) our ability to comply with financial covenants contained in our credit agreements and our debt instruments; (5) a delay in resolution of the Company's tax audits and an adverse determination with respect to the Company's tax audits by the Internal Revenue Service or other taxing authorities; (6) cyclical downturns continuing to affect several of the industries into which we sell our products; (7) our ability to adjust our operations to address unexpected changes; (8) our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business; (9) the loss of any of our licenses that may require us to stop selling products or lose competitive advantage; (10) competition; (11) regulatory compliance; (12) regulatory changes; (13) our failure to obtain and enforce intellectual property protection; (14) our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets; (15) other factors which we describe under the caption "Forward-Looking Information and Factors Affecting Future Performance" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information

Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.7 billion in 2004, has 10,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.